News | Stent Grafts | June 13, 2018

FDA Committee Votes in Favor of Incraft AAA Stent Graft System

Cardinal Health device designed for the endovascular treatment of infrarenal abdominal aortic aneurysms

FDA Committee Votes in Favor of Incraft AAA Stent Graft System

June 13, 2018 — Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable recommendation on its premarket approval application from a key U.S. Food and Drug Administration (FDA) panel. The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted 11 to 4 in favor of the benefits of the device.

The Incraft system is an advanced endovascular aneurysm repair (EVAR) technology for the treatment of infrarenal abdominal aortic aneurysms (AAAs), a severe and complex condition.

An abdominal aortic aneurysm is a bulging, weakened area in the wall of the lower part of the aorta, the main artery of the body, which, unless treated, can rupture and lead to a life-threatening hemorrhage. An estimated 1.5 million people in the United States have AAA, and more than 200,000 new diagnoses are made each year.1 These aneurysms account for approximately 10,000 deaths annually in the United States.2 Once identified, treatment options for AAAs include medical monitoring, open surgical repair or EVAR, a minimally invasive endovascular treatment option with the potential to reduce perioperative mortality and morbidity.

While several EVAR devices are currently available in the U.S., treatment options are limited for many AAA patients with small femoral or iliac arteries or with heavily calcified or tortuous vessels that could lead to complications during the introduction of EVAR devices.

The Incraft system is an ultra-low profile and flexible stent-graft system designed to prevent rupture of infrarenal AAAs in a wide range of patient populations.

The favorable vote of the advisory committee followed a review of clinical data from the pivotal INSPIRATION trial. The prospective, multi-center, single-arm study evaluated the safety and effectiveness of the Incraft system in patients with AAA. The trial showed that the Incraft system met the primary safety and effectiveness endpoints, with a low rate of major adverse events at 30 days and a high rate of successful aneurysm treatment at 1 year.3 As presented at the Circulatory System Devices Panel meeting, the trial demonstrated high survival of nearly 80 percent and no aneurysm ruptures through four years of follow up.

The Incraft system, which received a CE mark in 2014, is commercially available in 39 countries. It is an investigational device not available for sale in the United States.

 

For more information: www.cardinalhealth.com

 

References

1. Lifetime Risk and Risk Factors for Abdominal Aortic Aneurysm in a 24 Year Prospective Study: the ARIC Study. Atherosclerosis, Thrombosis, and Vascular Biology. 2016;36:2468-2477

2. Centers for Disease Control and Prevention (CDC), 2017

3. Ohki, One-Year Outcomes of the INSPIRATION Study of the INCRAFT® Stent-Graft System for Treatment of Abdominal Aortic Aneurysms (AAAs), Society for Vascular Surgery 2015


Related Content

News | Endovascular Aortic Repair

June 19, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home June 19, 2024
Home
News | Endovascular Aortic Repair

October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research ...

Home October 30, 2023
Home
News | Endovascular Aortic Repair

December 5, 2022 — Imagen Technologies, Inc. announced the U.S. Food and Drug Administration's 510(k) clearance of the ...

Home December 05, 2022
Home
News | Endovascular Aortic Repair

October 26, 2022 — Thousands of people have new hope for treatment of thoracic aortic arch disease and University ...

Home October 26, 2022
Home
News | Endovascular Aortic Repair

March 22, 2022 – A retrospective evaluation of 600 fenestrated-branched endovascular aortic repairs for the treatment of ...

Home March 22, 2022
Home
News | Endovascular Aortic Repair

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

Home February 18, 2022
Home
News | Endovascular Aortic Repair

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
News | Endovascular Aortic Repair

February 23, 2021 — Medtronic has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent ...

Home February 23, 2021
Home
News | Endovascular Aortic Repair

January 31, 2020 – The Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) released new reporting ...

Home January 31, 2020
Home
News | Endovascular Aortic Repair

January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with abdominal aortic aneurysms (AAA) ...

Home January 29, 2020
Home
Subscribe Now